ELI LILLY & Co
CIK 59478 · Director, Chairman and CEO · last filed 2023-08-14
ELI LILLY & Co is a Director, Chairman and CEO who has filed 26 SEC Form 4 insider transactions across 10 companies since 2010. The most recent filing shows the insider bought $25.6M of SGTX on Aug 14, 2023. Across all open-market trades the lifetime net is +$777.1M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $3.09B across reported positions. 483 SEC filings were submitted jointly with LILLY ENDOWMENT INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DERM price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
DROP CODE 1094
INDIANAPOLIS, IN 46285
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Sigilon Therapeutics, Inc. (SGTX) Delisted | 10%+ Owner | 100 | $22.47 | $2.2K | $31.04M | 2 | 2023-08-14 |
| RNA | 10%+ Owner | 2,169,396 | $6.64 | $14.40M | $0 | 1 | 2020-06-16 |
| DERM | 10%+ Owner | 100 | $3.69 | $369 | $767.36M | 1 | 2020-02-20 |
| ELAN | 10%+ Owner | 0 | $26.70 | $0 | $0 | 1 | 2019-03-11 |
| ZYME | 10%+ Owner | 1,827,101 | $26.04 | $47.58M | -$15.35M | 14 | 2019-02-06 |
| CYPHERPUNK TECHNOLOGIES INC. (LPTX) Delisted | 10%+ Owner | — | $1.56 | — | $0 | 1 | 2018-08-13 |
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | 10%+ Owner | 100 | — | — | $0 | 1 | 2017-03-01 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | 10%+ Owner | 102,742 | $12.01 | $1.23M | $5.00M | 1 | 2016-04-14 |
| Receptos, Inc. (RCPT) Delisted | 10%+ Owner | 2,081,210 | — | — | $2.00M | 1 | 2013-11-21 |
| UTHR | 10%+ Owner | 5,251,394 | $577.34 | $3.03B | -$12.96M | 3 | 2011-07-06 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| AGLE | Lilly Ventures Fund I LLC by fund |
102,742 | 100.0% | 2016-04-14 |
| Total | 102,742 | |||
| RCPT | Lilly Ventures Fund I LLC by Group |
2,081,210 | 100.0% | 2013-11-21 |
| Total | 2,081,210 |
Recent Filings
26 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-08-14 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Buy (P) | +1,718,493 | $25.64M | EDGAR |
| 2020-12-10 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Mixed | +2,744,443 | $5.40M | EDGAR |
| 2020-06-16 | RNA | Conv (C) | +2,169,396 | $0 | EDGAR |
| 2020-02-20 | DERM | Buy (P) | +40,926,025 | $767.36M | EDGAR |
| 2019-03-11 | ELAN | Disp (D) | −293,290,000 | $0 | EDGAR |
| 2019-02-06 | ZYME | — | — | $0 | EDGAR |
| 2019-02-04 | ZYME | Sell (S) | −250,000 | -$4.00M | EDGAR |
| 2018-11-08 | ZYME | Sell (S) | −700,000 | -$9.80M | EDGAR |
| 2018-09-26 | ZYME | Sell (S) | −2,027 | -$33.2K | EDGAR |
| 2018-09-20 | ZYME | Sell (S) | −6,870 | -$100.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).